Long-term follow-up analysis of relapse after dupilumab discontinuation in pediatric patients with moderate-to-severe atopic dermatitis: A retrospective study from China

Long-term follow-up analysis of relapse after dupilumab discontinuation in pediatric patients with moderate-to-severe atopic dermatitis: A retrospective study from China | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 8 August 2025 V1 Latest version Share on Long-term follow-up analysis of relapse after dupilumab discontinuation in pediatric patients with moderate-to-severe atopic dermatitis: A retrospective study from China Authors : Qin Lu , Ling Na , Jinling Liu , Xiangzhi Wang , and LanFang Tang 0000-0002-7994-7066 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.175465461.13893101/v1 353 views 102 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Objective: Dupilumab has been demonstrated to be an effective and safe treatment for atopic dermatitis (AD) in pediatric patients in clinical trials. However, data on post-discontinuation relapse are scarce. This study aimed to evaluate relapse patterns and identify predictive factors for disease recurrence in pediatric patients with moderate-to-severe AD following dupilumab discontinuation. Methods: This retrospective study analyzed 37 children (aged 3–13 years) treated with dupilumab (≥16 weeks) from July 2021 to June 2022, with follow-up until May 2025. Disease relapse was defined as a clinically significant exacerbation requiring therapeutic intervention. Baseline characteristics, treatment duration, and laboratory markers were assessed. The primary outcome measures included the relapse rate and median time to relapse after treatment discontinuation. Additionally, predictors for relapse were explored. Results: Within 144 weeks after discontinuation, 73.0% of patients (27/37) experienced relapse. The median time to relapse was 150 days, with no significant difference between dupilumab monotherapy and dupilumab + subcutaneous immunotherapy (SCIT) (p=0.676). Younger age at disease onset (HR=0.70, p=0.046) and lower baseline eosinophil count (HR=0.23, p=0.021) independently predicted earlier relapse. Most discontinuations (78.3%) occurred because disease control was achieved. Conclusions: This study provided critical real-world data on relapse, with a high rate (73.0%) and a median time to recurrence of approximately 150 days. Combination therapy with SCIT did not significantly alter recurrence. Younger age at onset and low eosinophil levels may help identify children at greater risk of postdupilumab relapse. Treatment discontinuation primarily reflects therapeutic success, underscoring the real-world effectiveness of dupilumab in pediatric AD patients. Supplementary Material File (paper.doc) Download 258.00 KB File (tables.doc) Download 71.00 KB Information & Authors Information Version history V1 Version 1 08 August 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Authors Affiliations Qin Lu Zhejiang University School of Medicine Children's Hospital View all articles by this author Ling Na Zhejiang University School of Medicine Children's Hospital View all articles by this author Jinling Liu Zhejiang University School of Medicine Children's Hospital View all articles by this author Xiangzhi Wang Zhejiang University School of Medicine Children's Hospital View all articles by this author LanFang Tang 0000-0002-7994-7066 [email protected] Zhejiang University School of Medicine Children's Hospital View all articles by this author Metrics & Citations Metrics Article Usage 353 views 102 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Qin Lu, Ling Na, Jinling Liu, et al. Long-term follow-up analysis of relapse after dupilumab discontinuation in pediatric patients with moderate-to-severe atopic dermatitis: A retrospective study from China. Authorea . 08 August 2025. DOI: https://doi.org/10.22541/au.175465461.13893101/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.175465461.13893101/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9ffe4d0aafbe1640',t:'MTc3OTQ3ODkxMw=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();